Loading…

Scutellarein inhibits RANKL‐induced osteoclast formation in vitro and prevents LPS‐induced bone loss in vivo

Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2019-07, Vol.234 (7), p.11951-11959
Main Authors: Fu, Fangsheng, Shao, Siyuan, Wang, Ziyi, Song, Fangming, Lin, Xixi, Ding, Jiaxin, Li, Chen, Wu, Zuoxing, Li, Kai, Xiao, Yu, Su, Yiji, Zhao, Jinmin, Liu, Qian, Xu, Jiake
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoporosis, arthritis, Peget's disease, bone tumor, periprosthetic joint infection, and periprosthetic loosening have a common characteristic of osteolysis, which is characterized by the enhanced osteoclastic bone resorptive function. At present, the treatment target of these diseases is to interfere with osteoclastic formation and function. Scutellarein (Scu), a flavonoids compound, can inhibit the progress of tumor and inflammation. However, the role of Scu in inflammatory osteolysis isn’t elucidated clearly. Our study showed that Scu inhibited bone destruction induced by LPS in vivo and OC morphology and function induced by RANKL in vitro. Mechanistic studies revealed that Scu suppressed osteoclastic marker gene expression by RANKL‐induced, such as Ctsk9, Mmp9, Acp5, and Atp6v0d2. In addition, we found that the inhibition effects of osteoclastogenesis and bone resorption function of Scu were mediated via attenuating NF‐κB and NFAT signaling pathways. In conclusion, the results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis. Scutellarein could inhibit osteoclastogenesis and bone resorptive function via attenuating NF‐κB and NFAT signaling pathways. The results showed that Scu may become a potential new drug for the treatment of inflammatory osteolysis.
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.27888